GALDERMA LABS LP
Big PharmaGALDERMA LABS LP is a major pharmaceutical company focused on Dermatology, Immunology. Key products include MIRVASO.
FDA Novel Drug Designations
(2019-2024)GALDERMA LABS LP's Key Drugs
GALDERMA LABS LP's core commercial portfolio centers on NEMLUVIO, AKLIEF, MIRVASO, spanning Dermatology and Immunology — its most strategically important drugs approved in the last 15 years.
Prurigo Nodularis
Acne Vulgaris
Rosacea
Rosacea
GALDERMA LABS LP's Recent FDA Approvals
GALDERMA LABS LP secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
GALDERMA LABS LP's Therapeutic Areas
GALDERMA LABS LP's approved drugs and pipeline span 2 therapeutic areas, led by Dermatology and Immunology, across 0 biologic and 14 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GALDERMA LABS LP's Top Competitors
GALDERMA LABS LP's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GALDERMA LABS LP Pipeline Snapshot
Active clinical trials for GALDERMA LABS LP across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (5)
Discontinued (0)
Company Info
- First Approval
- 1984-12-14
- Latest
- 2026-05-22
- Applications
- 27